The use of evidence in pharmacovigilance -: Case reports as the reference source for drug withdrawals

被引:55
作者
Arnaiz, JA
Carné, X
Codina, C
Ribas, J
Trilla, A
机构
[1] Hosp Clin, UASP, Barcelona 08036, Spain
[2] Hosp Clin, Hosp Pharm, Barcelona, Spain
[3] Hosp Clin, Unit Assessment Support & Prevent, Barcelona, Spain
关键词
pharmacovigilance; adverse drug reaction; drug withdrawal;
D O I
10.1007/s002280100265
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: Withdrawal of a drug from the market for safety reasons is a serious and sometimes complex decision. The scientific evidence supporting drug withdrawals in the past years is critically appraised, Methods: With data provided by the Spanish Medicines Agency, all drugs withdrawn from the Spanish market for safety reasons from January 1990 to December 1999 were identified. The adverse drug reactions (ADRs) were classified by the year of withdrawal, by the organ/system affected and by the alleged type of reaction (Rawlins and Thompson classification). A systematic review of the literature was performed. Results: A total of 22 drugs were withdrawn from the market due to safety reasons. In 18 of 22 cases (82%), the evidence supporting the drug withdrawal came from individual case reports, cases series or the combination of data provided by randomised clinical trials and case reports. Hepatic (eight cases) and cardiac (five cases) reactions accounted for 59% (13 of 22) of the total withdrawals. In 10 of 22 (45%) cases, drug withdrawal was clearly due to type-B reactions. Only four withdrawals were based on evidence from observational studies inducting a comparison group. Conclusion: Case reports are the main source of information used to withdraw a drug from the market for safety reasons. It is necessary to improve the quality of evidence supporting the withdrawal process of drugs linked to unexpected and severe ADRs. The use of large databases to perform cohort or nested case-control analyses is the most efficient and reliable method to study type-A class effect ADRs, The implementation of such databases in different countries could increase the quality of the information on ADRs by allowing researchers to conduct efficiently these type of studies.
引用
收藏
页码:89 / 91
页数:3
相关论文
共 10 条
[1]   Methodological and political issues in clinical pharmacology research by the year 2000 [J].
Carné, X ;
Arnaiz, JA .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 55 (11-12) :781-785
[2]   Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding:: population based case-control study [J].
de Abajo, FJ ;
Rodríguez, LAG ;
Montero, D .
BRITISH MEDICAL JOURNAL, 1999, 319 (7217) :1106-1109
[3]  
FARLEY TMM, 1995, LANCET, V346, P1582
[4]   CRITICAL-APPRAISAL OF PUBLISHED RESEARCH - INTRODUCTORY GUIDELINES [J].
FOWKES, FGR ;
FULTON, PM .
BRITISH MEDICAL JOURNAL, 1991, 302 (6785) :1136-1140
[5]   RISK OF IDIOPATHIC CARDIOVASCULAR DEATH AND NONFATAL VENOUS THROMBOEMBOLISM IN WOMEN USING ORAL-CONTRACEPTIVES WITH DIFFERING PROGESTAGEN COMPONENTS [J].
JICK, H ;
JICK, SS ;
GUREWICH, V ;
MYERS, MW ;
VASILAKIS, C .
LANCET, 1995, 346 (8990) :1589-1593
[6]   Fatal aplastic anaemia associated with nifedipine [J].
Laporte, JR ;
Ibáñez, L ;
Ballarín, E ;
Pérez, E ;
Vidal, X .
LANCET, 1998, 352 (9128) :619-620
[7]   UPPER GASTROINTESTINAL-BLEEDING IN RELATION TO PREVIOUS USE OF ANALGESICS AND NONSTEROIDAL ANTIINFLAMMATORY DRUGS [J].
LAPORTE, JR ;
CARNE, X ;
VIDAL, X ;
MORENO, V ;
JUAN, J .
LANCET, 1991, 337 (8733) :85-89
[8]  
Rawlins JW., 1977, TXB ADVERSE DRUG REA, P44
[9]  
Spitzer WO, 1996, BRIT MED J, V312, P83
[10]   IDENTIFICATION OF ADVERSE REACTIONS TO NEW DRUGS .3. ALERTING PROCESSES AND EARLY WARNING SYSTEMS [J].
VENNING, GR .
BRITISH MEDICAL JOURNAL, 1983, 286 (6363) :458-460